Large Unstained Cells (LUC): A Novel Predictor of CDK4/6 Inhibitor Outcomes in HR+ HER2-Negative Metastatic Breast Cancer
Authors:
- Furkan CeylanFCFurkan Ceylan
- Mirmehdi MehdiyevMMMirmehdi Mehdiyev
- Didem Şener DedeDDDidem Şener Dede
- Safa Can EfilSESafa Can Efil
- Ateş Kutay TenekeciATAteş Kutay Tenekeci
- Burak BilginBBBurak Bilgin
- Şebnem YücelŞYŞebnem Yücel
- Hayriye Tatlı DoğanHDHayriye Tatlı Doğan
- Mehmet Ali Nahit ŞendurMŞMehmet Ali Nahit Şendur
- Muhammed Bülent AkıncıMAMuhammed Bülent Akıncı
- Doğan UncuDUDoğan Uncu
- Bülent YalçınBYBülent Yalçın
Open Access
- 31 December 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (1) , 173
Abstract
Background: Although CDK4/6 inhibitors combined with endocrine therapies have improved outcomes in HR+ HER2-negative metastatic breast cancer, predictive biomarkers for treatment response and adverse effects remain limited. This study assessed the prognostic and predictive value of large unstained cells (LUC), a subset of white blood cells that may reflect immune status or treatment response. Methods: A retrospective analysis of 210 patients with HR+ HER2-negative metastatic breast cancer treated with CDK 4/6 inhibitors between 2021 and 2024 was conducted. Clinical data, including demographics, tumor characteristics, and treatment regimens, were analyzed. Based on LUC levels, progression-free survival (PFS), overall survival (OS), and adverse events were evaluated. Results: The cohort had a median age of 57, of which 78% were postmenopausal. Common metastatic sites included bone (67%) and liver (24%). At a median follow-up of 18.5 months, the PFS and OS rates were 65% and 83%. Patients with low LUC levels had significantly shorter PFS (OR: 1.91; p = 0.014) and OS (OR: 2.39; p = 0.012), while high LUC levels correlated with a lower incidence of grade 3 neutropenia (OR: 0.49; p = 0.017). Liver metastasis and prior treatments were also linked to shorter survival. Conclusions: LUC levels emerge as a promising biomarker for predicting survival outcomes and the risk of neutropenia in HR+ HER2-negative metastatic breast cancer patients treated with CDK 4/6 inhibitors and endocrine therapy, showing their potential to guide personalized treatment approaches.Keywords
This publication has 42 references indexed in Scilit:
- Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitorsCancer Chemotherapy and Pharmacology, 2024
- The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysisBreast Cancer Research and Treatment, 2024
- The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective studyThe Breast, 2023
- Role of large unstained cells in predicting successful stem cell collection in autologous stem cell transplantationTransfusion and Apheresis Science, 2022
- Overall Survival with Ribociclib plus Letrozole in Advanced Breast CancerNew England Journal of Medicine, 2022
- Clinical and laboratory features of COVID-19: Predictors of severe prognosisInternational Immunopharmacology, 2020
- Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: A systematic reviewEuropean Journal of Cancer, 2020
- Tumor-associated macrophages in breast cancer: Innocent bystander or important player?Cancer Treatment Reviews, 2018
- Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancerBreast Cancer Research and Treatment, 2017
- Flow cytochemical analysis of peripheral lymphocytes in chronic B-lymphocytic leukemia. Prognostic role of the blast count determined by the H∗1 system and its correlation with morphologic featuresLeukemia Research, 1992